AbbVie remains strong long-term performer, offering a solid dividend yield and robust revenue growth despite share price dips ...

DelveInsight’s, “Schizophrenia Pipeline Insight” report provides comprehensive insights about 55+ companies and 60+ pipeline ...

While emraclidine did not perform as expected, AbbVie management said today at the J.P. Morgan Healthcare Conference that they still see signs of hope in the medication's clinical trial results ...

AbbVie said the impairment charge is related to last year’s $8.7 billion bet on Cerevel following the failure of the deal’s key drug candidate, emraclidine, a schizophrenia treatment .

Investing.com -- AbbVie (NYSE: ABBV), a global biopharmaceutical company, has announced plans to record a non-cash after-tax intangible asset impairment charge. The charge, which is related to the ...

The failure of Cerevel's emraclidine in schizophrenia will cost AbbVie an impairment charge of about $3.5 billion, the pharma said in a Jan. 10 filing with the Securities and Exchange Commission.

The charge, which is related to the emraclidine intangible asset, is expected to be approximately $3.5 billion. Emraclidine is a drug currently under development for the treatment of schizophrenia ...

Emraclidine is a drug currently under development for the treatment of schizophrenia and Alzheimer’s disease. The drug was acquired as part of AbbVie's purchase of Cerevel Therapeutics.

Emraclidine was part of AbbVie's acquisition of Cerevel last year, which also included Tavapadon, which reported positive Phase 3 data. Bristol's Cobenfy is now poised to dominate the ...

AbbVie's emraclidine setback in phase 2 trials impacts neuroscience pipeline, benefitting Bristol Myers Squibb's Cobenfy in muscarinic drug class. Learn more on ABBV stock here.

In early August, it closed a deal valued at $8.7 billion to acquire emraclidine's developer, Cerevel Therapeutics. The schizophrenia drug was one of the main reasons AbbVie bought the company.